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Abstract
Background: Malaria infections are often genetically diverse, potentially leading to competition
between co-infecting strains. Such competition is of key importance in the spread of drug
resistance.
Methods: The effects of drug treatment on within-host competition were studied using the rodent
malaria Plasmodium chabaudi. Mice were infected simultaneously with a drug-resistant and a drug-
sensitive clone and were then either drug-treated or left untreated. Transmission was assessed by
feeding mice to Anopheles stephensi mosquitoes.
Results: In the absence of drugs, the sensitive clone competitively suppressed the resistant clone;
this resulted in lower asexual parasite densities and also reduced transmission to the mosquito
vector. Drug treatment, however, allowed the resistant clone to fill the ecological space emptied
by the removal of the sensitive clone, allowing it to transmit as well as it would have done in the
absence of competition.
Conclusion:  These results show that under drug pressure, resistant strains can have two
advantages: (1) they survive better than sensitive strains and (2) they can exploit the opportunities
presented by the removal of their competitors. When mixed infections are common, such effects
could increase the spread of drug resistance.
Background
Malaria infections often consist of more than one parasite
genotype [1-3]. Humans represent ecological niches for
co-infecting malaria parasites, with shared predators
(immune responses) and limited resources, so that com-
petition between co-infecting malaria strains is likely to be
intense [4]. Such competition could strongly affect the rel-
ative transmission of newly arisen drug-resistant strains,
and thus the spread of drug resistance [5].
Resistant and sensitive strains will co-occur in the same
host both when de novo mutations arise, and when hosts
acquire resistant and sensitive strains from one mosquito
bite simultaneously or from different mosquito bites. In
the absence of drug treatment, the transmission success of
the resistant strain will depend on its intrinsic fitness and
competitive ability. However, if drug treatment does
occur, the resistant strain has two potential fitness advan-
tages. First, it will better survive the drug than the sensitive
strain. Second, treatment can remove drug-sensitive
Published: 14 September 2004
Malaria Journal 2004, 3:33 doi:10.1186/1475-2875-3-33
Received: 15 June 2004
Accepted: 14 September 2004
This article is available from: http://www.malariajournal.com/content/3/1/33
© 2004 de Roode et al; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Malaria Journal 2004, 3:33 http://www.malariajournal.com/content/3/1/33
Page 2 of 6
(page number not for citation purposes)
competitors, thus freeing up ecological space for the resist-
ant strains to occupy; this would increase the relative
transmission of the drug-resistant strain. This second
effect, well recognized in theory, has the potential to
greatly enhance the rate of spread of drug resistance in a
population [5]. However, there is no direct experimental
evidence that removal of competitors by drug treatment
does enhance the transmission of drug-resistant parasites.
This paper reports the first direct experimental demonstra-
tion that competitive release of drug-resistant strains can
occur following drug treatment.
Competition between drug-sensitive and -resistant
malaria clones was studied using the rodent malaria Plas-
modium chabaudi. This parasite is commonly used as a
model for human malaria [6], and has been extensively
used to study drug resistance [7]. In the absence of drugs,
the drug-resistant clone is competitively suppressed by a
drug-sensitive clone [8]. Here, competition between the
two strains in drug-treated and untreated mice is
compared.
Methods
Two genetically distinct Plasmodium chabaudi chabaudi
clones were used: an AS clone resistant to the antifolate
drug pyrimethamine [9], and AJ, a sensitive clone. These
clones will be referred to as R (for resistant) and S (for sen-
sitive) from hereon. Hosts were eight weeks old CBA/Ca
inbred female mice (Ann Walker, University of Edin-
burgh; Harlan, England). Two experiments were per-
formed. In the first, two groups of five mice were infected
with 106 R parasites, and two groups with 106 R + 106 S
parasites, as described elsewhere [8]. One group from
each of these two infection types was drug-treated within
three hours of inoculation and again on days 1, 2 and 3 PI
(post-infection), using an oral administration of 8 mg
pyrimethamine per kg mouse body weight.
Asexual parasite densities and gametocyte densities – the
latter being the transmission stages to the mosquito –
were monitored using microscopic examination of thin
blood smears and determination of red blood cell densi-
ties using flow cytometry (Beckman Coulter), as described
elsewhere [8]. Real-time quantitative PCR was used to dis-
tinguish and quantify R and S parasites in mixed infec-
tions [8,10]. This protocol cannot distinguish between
asexual parasites and gametocytes, but real-time PCR data
were used as estimates of asexual densities, because game-
tocyte densities were 2–3 orders of magnitude lower than
asexual densities and thus a negligible component of
overall parasite numbers. For each infection, two phases
were distinguished: the acute phase, involving the first
wave of parasites, and the chronic phase, beginning when
parasite numbers began to recover after the collapse of
that first wave around day 12. All parasites had disap-
peared below detectable levels after 50 days.
In the second experiment, two groups of nine mice were
infected as above with either R parasites or R+S parasites.
The subsequent transmission success of clone R was
assayed by allowing batches of 30 starved Anopheles
stephensi mosquitoes to feed on 3 mice from each group
on each of days 7, 14, and 21 PI, as described elsewhere
[e.g. [11]]. Eight days after the feeds, mosquitoes were dis-
sected, and DNA extracted from midguts carrying oocysts.
Real-time quantitative PCR was subsequently used to
determine the prevalence of clone R in these mosquitoes.
All procedures were regulated and carried out under the
British Home Office Animals (Scientific Procedures) Act
1986.
Results
Two untreated mice infected with R+S parasites died on
days 10 and 11 PI respectively, and were excluded from
the analysis.
In untreated mice, there were far fewer R parasites during
the acute phase in mixed infections with clone S than in
R-only infections (Figures 1a,1c). However, in drug-
treated mice, where S parasites were entirely removed by
pyrimethamine (none of the PCR reactions performed
were positive for clone S), there were as many R parasites
in mixed infections as there were in R-only infections (Fig-
ures 1b,1c; Drug treatment × Alone/Mixed interaction:
F1,14 = 14.4, p = 0.002). Thus, R parasites were competi-
tively suppressed in mixed infections in untreated mice,
but this suppression was negated when mice were treated
with pyrimethamine, which effectively removed S
parasites.
During the chronic phase, clone R was more numerous in
untreated mice in mixed infections than in single-clone
infections (due to the parasite peak around day 21; Fig-
ures 1a,1d). Thus, in untreated mice in the chronic phase,
clone R did not suffer from competition, and actually ben-
efited from the presence of clone S (facilitation). In drug-
treated mice, however, R parasites were similarly numer-
ous in mixed- and single- clone infections (Figures 1b,1d;
Drug treatment × Alone/Mixed interaction: F1,14 = 13.8, p
= 0.002).
The large peak of R parasites in the chronic phase in the
untreated mixed infections around day 21 (Figure 1a)
coincided with a large peak of gametocytes, the transmis-
sible stages of the parasite (Figure 2a). This was in contrast
with single-clone infections of R in untreated mice, and
infections in drug-treated mice, where gametocytes were
mainly produced around day 14 (Figures 2a,2b). Overall,Malaria Journal 2004, 3:33 http://www.malariajournal.com/content/3/1/33
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gametocyte numbers were the same for all four infection
types (p > 0.05 for both Drug treatment and Alone/
Mixed). Whether clone R really suffered from competitive
suppression by clone S in untreated mice thus depends on
how many of the gametocytes around day 21 were of the
R genotype, and on how transmissible they were.
The second experiment assessed transmission to mosqui-
toes on days 7, 14 and 21 PI. It was found that the resist-
ant clone R infected far fewer mosquitoes from mixed
infections than from single infections (figure 3; Alone/
Mixed: p = 0.002), indicating that transmissibility of
gametocytes produced around day 21 was low, probably
as a result of transmission-blocking immunity [12]. Thus,
the competitive suppression of the resistant clone in
untreated infections translated into reduced transmission
success.
Discussion
These results show that drug treatment of malaria infec-
tions can severely affect ecological interactions between
co-infecting strains. The drug-resistant clone was compet-
itively suppressed by the drug-sensitive clone in untreated
mice, in terms of both within-host growth and transmis-
sion to the mosquito vector. However, drug treatment
removed that competitive suppression, and allowed the
resistant clone to fill the ecological space emptied, giving
it a substantial and additional fitness benefit in addition
Log asexual parasite densities of the resistant clone R over time in untreated (a) and drug-treated (b) mice infected with R  alone or a mixture of R+S clones, and total numbers of R parasites produced over the acute (c) and chronic phases (d) Figure 1
Log asexual parasite densities of the resistant clone R over time in untreated (a) and drug-treated (b) mice infected with R 
alone or a mixture of R+S clones, and total numbers of R parasites produced over the acute (c) and chronic phases (d). All data 
points (mean ± 1 s.e.m.) are based on 5 replicate mice, except for mixed infections in untreated mice in (a) (4 mice on day 11 
and 3 mice from day 12 onwards) and (c) and (d) (3 mice). As the limit of detection was 100 parasites per µl blood, y-axes in 
(a) and (b) start at 2.
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to the simple survival advantage conferred by resistance.
Thus, under drug pressure, resistant strains can have two
advantages: they survive better than sensitive strains and
they can exploit the opportunities presented by the
removal of their competitors, thereby increasing their rel-
ative transmission. Competition was studied between two
unrelated clones, and thus did not reflect the situation in
which a resistant clone arose de novo [13], but it seems
likely that the competitive release following drug therapy
would also apply there.
Competitive release following drug treatment will greatly
enhance the spread of drug resistance [5]. Also, with only
the resistant strain left in the host, the probability of
outbreeding is reduced, thus reducing the chances of mei-
otic recombination destroying multi-locus resistance [14].
In combination, these two processes could enhance the
spread of drug resistance, especially in areas with high
numbers of strains per infection [5].
Of course, this is an argument for judicious use of drugs,
not their non-use. Clearance of drug-sensitive strains from
mixed infections might enhance the spread of drug resist-
ance, but this has to be offset against the short-term public
health benefits, such as reducing overall malaria preva-
lence. In these experiments, the drug-sensitive clone was
Log gametocyte densities over time (mean ± 1 s.e.m.) for untreated (a) and drug-treated (b) mice Figure 2
Log gametocyte densities over time (mean ± 1 s.e.m.) for untreated (a) and drug-treated (b) mice. In (a) gametocyte densities 
for mixed R+S infections reflect overall R+S gametocytes, as the PCR assay could not distinguish between these (see text); in 
(b) all gametocytes are produced by clone R, as clone S was cleared from mixed infections. All data points are based on 5 rep-
licate mice, except for mixed infections in untreated mice in (a): 4 mice on day 11 and 3 mice from day 12 onwards. As the limit 
of detection was 100 gametocytes per µl blood, y-axes start at 2.
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Proportions of mosquitoes infected with the resistant clone 
R (mean and 95% confidence interval); mosquitoes fed either 
on mice infected with clone R alone or mice infected with a 
mixture of clones R and S. Means are based on 9 mice (3 on 
day 7, 3 on day 14 and 3 on day 21 PI) from which totals of 
205 (R alone) and 216 (mixed R+S) mosquitoes took a blood 
meal. Infection with clone R was assessed by real-time PCR.
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also the more virulent clone [8], and when it was cleared
from mixed infections by drug treatment, mice were less
sick, in that they lost less weight and became less anaemic
(results not shown).
In this experiment, mice were drug-treated before symp-
toms occurred, resulting in competitive release. This situ-
ation perhaps best mimics the case of prophylactic drug
use, or what might occur to new co-infections in high
transmission areas where drug use is common. A battery
of more complex experiments will be necessary to deter-
mine if competitive release occurs when treatment follows
symptoms, and when drugs are used to treat semi-
immune individuals. The facilitation observed in chronic
infections (Figures 1a,1d) suggests the situation might be
very complex.
Within-host competition in P. chabaudi is now firmly
established [8,15,16]. Evidence for competition between
co-infecting genotypes in human malaria infections is
necessarily indirect, but consistent with this [4]. In older
children and adults, for example, parasite densities do not
increase with increasing numbers of clones, thus indicat-
ing that parasite clones are not regulated independently
[17]. Given this, and the high frequency of mixed infec-
tions in human malaria [1-3,18] often consisting of both
resistant and sensitive genotypes [19], and the fact that
genetic diversity can be altered by antimalaria prophylaxis
[20], it is highly likely that competitive release of drug
resistance also occurs in human malaria. Indeed, a recent
study has already implicated release of within-host
competition as a key-factor in the spread of drug resist-
ance in Uganda [21].
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